SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

RVMD

Revolution Medicines, Inc.
BEARISH
Impact 7/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The offering is highly dilutive, over 12 million new shares issued at $142 represents ~8.5% dilution assuming ~143 million prior shares outstanding. While the cash strengthens the balance sheet for late-stage trials, the scale of dilution outweighs benefits in the near term. Traders should monitor short-term price pressure and assess whether future R&D milestones can offset sentiment around dilution.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$146.23
T+0 close · Apr 17, 2026 · via day close
Latest settled
+26.13%
T+60 · $184.44
Vs SPY
+19.35%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 20 $146.23entry
  2. T+1 · 7mo ago +1.83%α +2.48% · $148.90
  3. T+5 · 7mo ago −9.96%α −10.87% · $131.67
  4. T+20 · 6mo ago −1.27%α −5.47% · $144.37
  5. T+60 · 4mo ago +26.13%α +19.35% · $184.44
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines raised approximately $2.225 billion through a concurrent public offering of common stock and convertible notes, with net proceeds of $2.137 billion. The capital raise includes 12.15 million shares at $142 per share and $500 million in 0.50% convertible senior notes due 2033, marking a significant dilutive financing event. The funds will support R&D and commercialization efforts for its RAS-addicted cancer therapies.

Key Financial Metrics

Deal Value
$2.2B

Key Facts

  • Closed concurrent public offerings: 12,147,887 shares of common stock at $142/share and $500 million in 0.50% convertible senior notes due 2033
  • Gross proceeds: $2.225 billion; net proceeds: $2.137 billion after underwriting discounts and expenses
  • Convertible notes have a 0.50% coupon, mature May 1, 2033, and initial conversion price of $198.80 per share (40% premium to stock offering price)
  • Proceeds to be used for R&D, potential commercialization, G&A, and capital expenditures
  • J.P. Morgan, TD Cowen, and Guggenheim Securities acted as book-running managers

Financial Impact

Approximately $2.137 billion in net proceeds, but with substantial near-term dilution from equity issuance and potential future dilution from convertible notes

dilutioncashdebtequity

Risk Factors

  • Significant shareholder dilution from equity issuance
  • Future equity conversion risk from notes if stock price rises, increasing potential share count by ~2.5 million at initial conversion rate

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276479

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026